GlassScriptPhysician profile
Josiah To
NPI 1306575576
$3,391.80
in general payments reported to CMS, 2019-2025
13 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $445 · 2024: $1,685 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,391.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $782.82 | 2023-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Alcon Vision LLC | $709.90 | 2024-2025 | Clareon, Hydrus Microstent |
| Glaukos Corporation | $699.96 | 2023-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite, Idose |
| Amgen INC. | $236.02 | 2024-2025 | Tepezza |
| Abbvie INC. | $222.32 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $155.36 | 2023-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Eyepoint US, INC. | $137.59 | 2024 | |
| Genentech, INC. | $132.83 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $120.89 | 2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $119.57 | 2023-2024 | Syfovre |
| Sight Sciences, INC. | $34.19 | 2025 | Omni Surgical System |
| Dompe US, INC. | $23.01 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $17.34 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josiah To listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.